The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …

Background Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have
potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further …

Cytokines are believed to be crucial mediators of chronic intestinal inflammation in
inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) …

Abstract Background and Aims Janus kinase [JAK] inhibitors have shown efficacy in
ulcerative colitis [UC]. We studied the dose-response, efficacy, and safety of peficitinib, an …

Abstract Background and Aims Tofacitinib is an oral small molecule Janus kinase [JAK]
inhibitor for the treatment of ulcerative colitis. We report an integrated summary of tofacitinib …

Background & Aims Tofacitinib is an oral, small-molecule inhibitor of JAK approved in
several countries for the treatment of ulcerative colitis (UC). We report integrated safety …

Targeting cytokines in inflammatory bowel disease (IBD) is a useful clinical approach.
Potential therapies for IBD include regulatory T cell transfer to restore cytokine balance …

The expanding therapeutic armamentarium available for inflammatory bowel disease (IBD)
as well as multiple compounds in clinical development inevitably raises questions as to their …

Inflammatory bowel disease (IBD) is a group of chronic disorders of the gastrointestinal tract
comprising Crohn's disease (CD) and ulcerative colitis (UC). Their etiologies are unknown …

Abstract Background and Aims Oral systemic pan-Janus kinase [JAK] inhibition is effective
for ulcerative colitis [UC] but is limited by toxicities. We describe preclinical to clinical …